louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06943066: Pilates Exercises on Pain, Fatigue, Endurance, and Muscle Strength in Non-Specific Low Back Pain
Official title: The Effects of Pilates Exercises on Pain, Fatigue, Endurance, and Muscle Strength in Individuals With Non-Specific Low Back Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Low Back Pain
Keywords: exercise
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2025-04-24
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pilates exercises administered under the supervision of a physiotherapist on pain, endurance, and muscle strength in individuals with non-specific low back pain, and to determine which program is more beneficial and reliable.

Detailed description: The aim of this study is to compare the effects of different types of Pilates exercises administered under the supervision of a physiotherapist on pain, endurance, and muscle strength in individuals with non-specific low back pain, and to determine which program is more beneficial and reliable.

Eligibility criteria: Inclusion Criteria

* Aged between 18 and 60 years
* Non-specific low back pain for more than 12 weeks
* No clear pathological diagnosis
* Physically and cognitively capable of performing the exercises
* Pain level between 3 and 7 on the Visual Analog Scale (VAS) Exclusion Criteria
* Pregnancy
* Spinal surgery in the last 6 months
* Neurological or chronic systemic diseases
* Movement restriction due to severe pain

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 12 weeks
measure: Oswestry Disability Index
timeFrame: 12 weeks
measure: Fatigue Severity Scale
timeFrame: 12 weeks
measure: Heart Rate Variability
timeFrame: 12 weeks
measure: Trunk Flexor and Extensor Endurance Tests:
timeFrame: 12 weeks
measure: Plank Test
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Hazal GENÇ
state: None Selected
Study officials:
References:
Clinical trial NCT04846166: I-Smads in Periodontitis
Official title: Role of Inhibitor SMADs in Stage 3 Grade B Periodontitis Before and After Periodontal Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontitis
Treatment Adherence
Keywords: Smad
Periodontitis
Gingival crevicular fluid
Saliva
Lead sponsor: Bulent Ecevit University
Sponsor class: OTHER
First posted: 2021-04-15
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 1. group (Control): Periodontally and systemically healthy
2. group: Systemically healthy and periodontitis

Brief summary: Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20 periodontally healthy individuals were included in the study. Clinical periodontal measurements were recorded; periodontitis patients received non-surgical periodontal treatment, and GCF and saliva samples were obtained at baseline and one month after treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.


Eligibility criteria: Inclusion Criteria:

* Have at least 20 natural teeth, excluding third molars.
* Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations.
* Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss

Exclusion Criteria:

* History of systemic disease.
* Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
* Periodontal treatment during last 6 months that could affect periodontal status.
* Smoking.
* History of radiotherapy or chemotherapy.
* Current pregnancy, lactation or menopause.

Primary outcomes:
measure: TGF-β, Smad6, and Smad7 levels
timeFrame: baseline
Secondary outcomes:
measure: TGF-β, Smad6, and Smad7 levels
timeFrame: baseline and 1st month after treatment
Other outcomes:
Locations:
city: Ordu
country: Turkey
facility: Figen Öngöz Dede
Study officials:
References:
Clinical trial NCT06612866: Determination of the Biological Activity of Enriched Serums on Healthy Volunteers After Consumption of the Kera-Diet® Ingredient
Official title: Determination of the Biological Activity of Enriched Serums on Healthy Volunteers After Consumption of the Kera-Diet® Ingredient, CnC2024 - Kera-Diet®
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: BCF Life Sciences
Sponsor class: INDUSTRY
Collaborators: name: Clinic'n'Cell
name: University Hospital, Clermont-Ferrand
First posted: 2024-09-25
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The main objective of this study is, after collecting serum enriched with metabolites of interest resulting from the ingestion of the Kera-Diet® food supplement, to determine the influence of these sera enriched with circulating metabolites (versus naïve sera) on the behavior of human cell cultures, placed under stress conditions or not, in order to evaluate the benefit of these metabolites in maintaining cellular functions.


Eligibility criteria: Main inclusion Criteria:

* Liver function tests within reference norms.
* Kidney function tests within reference norms.
* Complete blood count (CBC) within reference norms.
* C-reactive protein (CRP) within reference norms.
* Blood pressure compatible with study requirements.
* Non-smoker or occasional smoker (max 5 cigarettes/day or max 10 ml per week of e-liquid with a nicotine concentration of 3 mg/ml).
* Max 5 hours of intense sports per week.
* Weight ≥ 60 kg.
* BMI between 20 and 28 kg/m² (exclusive).

Main exclusion Criteria:

* Any type of vaccination within the past month.
* Alcohol consumption exceeding WHO standards (Sup. 3 drinks per day for men).
* Ongoing treatment (medication, dietary supplement, or probiotic) and within the four weeks prior to inclusion.
* Known pathology (including seasonal).
* Allergy to the study product, particularly to keratin or certain amino acids.
* Individuals following a diet unsuitable for the study (e.g., vegetarian, vegan, or plant-based diets).
* Change in eating habits within the 4 weeks prior to inclusion.
* Medical and/or surgical history deemed incompatible with the trial by the investigator or their representative.

Primary outcomes:
measure: Determination of the influence of human serums enriched with circulating metabolites on human cell cultures
timeFrame: Determination of the absorption peak: kinetics will be determined by a blood draw at different time points (T0, T5, T10, T20, T30, T45, T60, T80, T100, T120, T140, T180, T240 minutes) over the 4 hours following the ingestion of the study product
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: University Hospital, Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Gisèle Pickering, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01041066: Nicardipine Versus Labetalol During Intubation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Patients Who Are Intubated for General Anesthesia
Endotracheal Intubation
Keywords: patients who are intubated for general anesthesia
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2009-12-31
Enrollment: 70
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study was to compare the efficacy of nicardipine and labetalol in attenuation of cardiovascular responses to endotracheal intubation.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled for general anesthesia with endotracheal intubation

Exclusion Criteria:

* Patients with heart failure or coronary artery disease 2-3 degree atrio-ventricular block or severe bradycardia (\< 45 beats/min) asthma, bronchial spasm or chronic obstructive pulmonary disease patients with anticipated difficult intubation (Mallampati class III, IV) severe hepatic or renal dysfunction allergy or contraindication to study medication

Primary outcomes:
measure: hemodynamic variables (systolic blood pressure, diastolic blood pressure and mean blood pressure, heart rate)
timeFrame: preinduction- 10 min after intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
References:
citation: Ryu JH, Apfel CC, Whelan R, Jeon YT, Hwang JW, Do SH, Ro YJ, Kim CS. Comparative prophylactic and therapeutic effects of intravenous labetalol 0.4 mg/kg and nicardipine 20 mug/kg on hypertensive responses to endotracheal intubation in patients undergoing elective surgeries with general anesthesia: a prospective, randomized, double-blind study. Clin Ther. 2012 Mar;34(3):593-604. doi: 10.1016/j.clinthera.2012.01.017. Epub 2012 Feb 24.
Clinical trial NCT00198666: Efficacy of Zinc in the Treatment of Pneumonia
Official title: Efficacy of Zinc in the Treatment of Pneumonia in Hospitalized Children Less Than 2 Years of Age
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia
Keywords: Pneumonia
zinc
Lead sponsor: Johns Hopkins Bloomberg School of Public Health
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 299
Sex: ALL
Maximum age (years): 23
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy of zinc supplementation in the treatment of children under the age of two years who have been hospitalized with severe pneumonia.

Detailed description: This study was a randomized, double-blind, placebo-controlled clinical trial conducted between September 2003 and August 2004 at the Christian Medical College (CMC) Hospital in Vellore, India. CMC Hospital is a large teaching hospital and medical center that is accessed directly by the population of Vellore and adjoining districts and by referrals from local medical practitioners.

Eligibility criteria: Inclusion Criteria:

* children under two years old hospitalized with Pneumonia

Exclusion Criteria:

* healthy children

Primary outcomes:
measure: Duration of severe symptoms
timeFrame: 2 years
Secondary outcomes:
measure: Time to recovery from severe pneumonia
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Johns Hopkins Bloomberg School of Public Health
name: Mathuram Santosham, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Coles CL, Bose A, Moses PD, Mathew L, Agarwal I, Mammen T, Santosham M. Infectious etiology modifies the treatment effect of zinc in severe pneumonia. Am J Clin Nutr. 2007 Aug;86(2):397-403. doi: 10.1093/ajcn/86.2.397.
Clinical trial NCT00411866: Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812
Official title: Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Schizophrenia
Keywords: safety
pharmacokinetics,
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2006-12-15
Enrollment: 36
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purposes of this study are to determine if there is a difference in how SB-773812 is distributed through the bloodstream before and after multiple doses of ketoconazole have been given and to determine if there is a difference in how safe and well tolerated SB-773812 is when given on its own and given with ketoconazole.


Eligibility criteria: Inclusion criteria:

* Healthy
* Body Weight \>/=50kg and BMI 18.5-29.9 kg/m2 inclusive
* Normal 12-lead ECG, physical examination and lab screen

Exclusion criteria:

* A history of psychiatric illness,
* A history or presence gastro-intestinal,
* A hepatic or renal disease or orthostatic hypotension.

Primary outcomes:
measure: Blood sampling over period of 336 hours post dosing with SB-773812
timeFrame: over period of 336 hours post dosing
Secondary outcomes:
measure: Safety: ECG, vital signs, adverse events, clinical labs over 48 hours post SB-773812 dosing.
timeFrame: over 48 hours post SB-773812 dosing.
Other outcomes:
Locations:
city: Dundee
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT06183866: Exposure to Chemical Substances Within Household Waste Incineration Plants
Official title: Evaluation of the Exposure to Chemical Substances of Some of the Employees Working in a Household Waste Incineration Plant
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Exposure to Chemical Pollution, Occupational
Keywords: Chemical Pollution
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-12-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult subject currently working, or having worked in the Strasbourg waste incineration plant between 01/01/2013 and 01/09/2022 within the maintenance or operating team

Brief summary: Employees of household waste incineration plants (UIOM) are exposed to multiple chemical substances that can pose a risk to their health.

The studies carried out find increases in certain toxic chemicals (heavy metals, dioxins), in the biological fluids of employees (blood, urine), in particular before the 2000s Another study conducted by Tait finds potential organic alterations.The investigators wish to complete the dissertation work with, in particular, an analysis of the quantitative elements of the exposure assessment (metrologies and biometrologies)

Detailed description: The aim of the study is to evaluate the recorded chemical exposures of certain employees of a household waste incineration plant (UIOM) in order to deduce the risk to their health.

Eligibility criteria: Inclusion criteria:

* Major subject (≥18 years old)
* Subject currently working, or having worked in the Strasbourg waste incineration plant between 01/01/2013 and 01/09/2022 within the maintenance or operating team
* Subject not objecting, after being informed, to the reuse of their data for the purposes of this research
* Subject in whom one or more biometrologies (blood lead level measurement, urinary cadmium level measurement, urinary 1-hydroxypyrene level measurement) were performed

Exclusion criteria:

-Subject who expressed their opposition to participating in the study

Primary outcomes:
measure: Retrospective evaluation of the identified chemical exposures of certain employees of a household waste incineration plant (UIOM) in order to deduce the risk to their health.
timeFrame: Files analysed retrospectively from 01 January 2013 to 01 September 2022 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Pathologie Professionnelle et Médecine du Travail - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT00843466: Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Official title: Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hand Dermatosis
Keywords: Hand dermatitis
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2009-02-13
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out if the use of a hand cleanser that adds moisture to the skin will help improve skin rashes caused by frequent hand washing (hand dermatitis).

Detailed description: The objective of this protocol is to evaluate compatibility and potential benefits of daily use of a marketed mild, moisturizing hand cleanser for subjects/patients who experience mild to moderate hand dermatitis induced by frequent cleansing.

Eligibility criteria: Inclusion Criteria:

* Between 18 and 65 years of age
* In general good health
* Hands free of cuts and abrasions
* Agree to adhere to the requirements listed in the informed consent
* Willing and able to use a mild, moisturizing, non-antibacterial cleanser for all hand washing purposes for the duration of the test period
* Willing to refrain from participating in any other clinical research trial for the duration of the study

Exclusion Criteria:

* Documented allergies to study product components, soaps, latex, or fragrances
* History of the following conditions which may affect the response of the skin or the interpretation of the results: insulin dependent diabetes, or peripheral vascular diseases
* Participating in a concurrent clinical study involving treatment of your hands
* Currently using a prescription medication for hand dermatitis

Primary outcomes:
measure: Investigator Global Assessment
timeFrame: Wk 4
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Wake Forest University Health Sciences Dermatology
state: North Carolina
Study officials:
affiliation: Wake Forest University Health Sciences
name: Alan Fleischer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03156166: Distance From the Glottis to the Grille in Children
Official title: Distance From the Glottis to the Grille in Children: Ambu AuraGainTM , I-gel, Air-Q Intubating Laryngeal Airway as Intubation Conduits
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-05-17
Enrollment: 89
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Ambu AuraGain, I-gel, Air-Q intubating laryngeal airway are the most commonly used supraglottic airway. In children, they can be used as intubation conduits. However, there has been no guideline for optimal insertion depth of endotracheal tube through those supraglottic airway. In this study, the investigators will measure the distance from grille of those supraglottic airways to glottis using fiberoptic bronchoscope in children undergoing anesthesia. This distance allows us to predict an appropriate depth of endotracheal tube when it should be inserted through each supraglottic airway.


Eligibility criteria: Inclusion Criteria:

* children \< 7 years old undergoing elective surgery

Exclusion Criteria:

* difficult airway
* BMI\> 30kg/m2
* emergency operation
* cervical spine disease
* history of esophageal disease and surgery

Primary outcomes:
measure: The distance from grille to glottis
timeFrame: 30 seconds after each supraglottic airway insertion
Secondary outcomes:
measure: FOB view
timeFrame: 30 seconds after each supraglottic airway insertion
measure: Ventilation score
timeFrame: 30 seconds after each supraglottic airway insertion
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lee JH, Park S, Jang YE, Kim EH, Kim HS, Kim JT. The distance between the glottis and the cuff of a tracheal tube placed through three supraglottic airway devices in children: A randomised controlled trial. Eur J Anaesthesiol. 2019 Oct;36(10):721-727. doi: 10.1097/EJA.0000000000001070.
Clinical trial NCT06671366: Test-retest Correlation in Isokinetic Shoulder Testing
Official title: Evaluation of Test-retest Correlation in Isokinetic Shoulder Testing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Isokinetic
Lead sponsor: Clinique Saint Jean, France
Sponsor class: OTHER
First posted: 2024-11-04
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study is a prospective, monocentric interventional clinical study in 30 healthy volunteers.

The aim is to objectively assess shoulder external and internal rotation strength using a Cybex dynamometer in a specific position (seated with the arm at 45° abduction and 30° elevation).

The investigator would like here to determine the reproducibility of measurements in this precise evaluation position, but also to determine reference values in healthy subjects.

The results of this study will enable us to improve our management and establish a database for comparison with pathological subjects.


Eligibility criteria: Inclusion Criteria:

* Student of the Montpellier School of Physical Therapy
* Adult having received informed information about the study and signed the consent form

Exclusion Criteria:

* Any history of shoulder pathology in the year preceding the tests.

Primary outcomes:
measure: Correlation between each measurement at peak torque
timeFrame: 1hour
Secondary outcomes:
measure: Data in healthy patients
timeFrame: 1hour
measure: Establishing the test's external validity
timeFrame: 1hour
Other outcomes:
Locations:
city: Saint Jean de Vedas
country: France
facility: Clinique St Jean Sud de France
Study officials:
References: